Sandostatin

Acromegaly, Flushing, Gastroenteritis + 4 more

Treatment

6 FDA approvals

17 Active Studies for Sandostatin

What is Sandostatin

Octreotide

The Generic name of this drug

Treatment Summary

Acromegaly is a disorder caused by too much growth hormone, resulting in abnormal growth in certain parts of the body, such as the face, hands, and feet. In most cases, it is caused by a tumor in the pituitary gland. Octreotide is a drug that mimics the natural hormone somatostatin to reduce growth hormone production. It's used to treat acromegaly and other tumor-related symptoms, and is usually given as an injection. On June 26, 2020, the first approved oral form of octreotide, called Mycapssa, was approved for long-term treatment of

Octreotide Acetate

is the brand name

image of different drug pills on a surface

Sandostatin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Octreotide Acetate

Octreotide

1988

89

Approved as Treatment by the FDA

Octreotide, otherwise known as Octreotide Acetate, is approved by the FDA for 6 uses such as metastatic Carcinoid Tumors and Gastroenteritis .

metastatic Carcinoid Tumors

Gastroenteritis

Diarrhea

Carcinoid Tumor

Acromegaly

Helps manage Acromegaly

Flushing

Effectiveness

How Sandostatin Affects Patients

Octreotide is a drug that works similar to the hormone somatostatin. It helps to control growth hormone and insulin levels in people with acromegaly, as well as reducing flushing and diarrhea caused by tumors in the digestive system. However, it can also reduce gallbladder contractility, bile secretion, and the release of thyroid-stimulating hormones in healthy people. There have also been reports that it can lower vitamin B12 levels, so it is important to monitor this in patients taking octreotide.

How Sandostatin works in the body

Octreotide works to reduce the effects of hormones that cause growth and other metabolic changes. It does this by binding to receptors in the blood vessels, which causes the muscles to contract. This process then leads to reduced growth hormone secretion, as well as a decrease in other hormones like luteinizing hormone (LH). Octreotide also reduces symptoms associated with carcinoid and VIPoma tumors, such as flushing and gastrointestinal distress.

When to interrupt dosage

The proposed amount of Sandostatin is contingent upon the determined condition, including Acromegaly, Vasoactive Intestinal Peptide Tumors and metastatic Carcinoid Tumors. The quantity of dosage fluctuates as per the technique of delivery (e.g. Injection - Intravenous; Subcutaneous or Capsule, delayed release) displayed in the table beneath.

Condition

Dosage

Administration

Flushing

, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL

Injection, solution, Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Kit - Intramuscular

Carcinoid Tumor

, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL

Injection, solution, Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Kit - Intramuscular

octreotide

, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL

Injection, solution, Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Kit - Intramuscular

Acromegaly

, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL

Injection, solution, Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Kit - Intramuscular

Gastroenteritis

, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL

Injection, solution, Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Kit - Intramuscular

Vasoactive Intestinal Peptide Tumors

, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL

Injection, solution, Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Kit - Intramuscular

long-term maintenance therapy

, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL

Injection, solution, Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Kit - Intramuscular

Warnings

Sandostatin Contraindications

Condition

Risk Level

Notes

known hypersensitivity to the drug or any of the ingredients

Do Not Combine

There are 20 known major drug interactions with Sandostatin.

Common Sandostatin Drug Interactions

Drug Name

Risk Level

Description

Dotatate gallium Ga-68

Major

Octreotide may decrease effectiveness of Dotatate gallium Ga-68 as a diagnostic agent.

Eliglustat

Major

The metabolism of Eliglustat can be decreased when combined with Octreotide.

Fentanyl

Major

The metabolism of Fentanyl can be decreased when combined with Octreotide.

Hydroxyzine

Major

The risk or severity of QTc prolongation can be increased when Octreotide is combined with Hydroxyzine.

Lutetium Lu 177 dotatate

Major

The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Octreotide.

Sandostatin Toxicity & Overdose Risk

Taking too much octreotide can cause low blood pressure, lack of oxygen to the brain, irregular heartbeat, and heart failure. Other side effects include high levels of lactic acid in the blood, inflammation of the pancreas, enlargement of the liver, diarrhea, redness of the skin, fatigue, and weakness.

image of a doctor in a lab doing drug, clinical research

Sandostatin Novel Uses: Which Conditions Have a Clinical Trial Featuring Sandostatin?

41 active trials are currently being conducted to examine the potential of Sandostatin to treat metastatic Carcinoid Tumors, provide long-term maintenance therapy and reduce Flushing symptoms.

Condition

Clinical Trials

Trial Phases

Acromegaly

6 Actively Recruiting

Phase 2, Phase 3, Phase 1

Flushing

0 Actively Recruiting

Gastroenteritis

12 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Early Phase 1

Vasoactive Intestinal Peptide Tumors

0 Actively Recruiting

Carcinoid Tumor

1 Actively Recruiting

Early Phase 1

long-term maintenance therapy

0 Actively Recruiting

octreotide

0 Actively Recruiting

Sandostatin Reviews: What are patients saying about Sandostatin?

5

Patient Review

5/27/2009

Sandostatin for Carcinoid Syndrome

I was diagnosed with carcinoid tumors in May 2007 and have been receiving shots from an oncologist since June 2007. So far, the treatment seems to be working well.

5

Patient Review

5/19/2010

Sandostatin for Carcinoid Syndrome

I've been getting this treatment every 28 days and it's been working really well so far. I have noticed that my blood sugar levels fall sometimes after the injection, which can make me feel shaky. But overall, it's been a positive experience and I'm glad I checked it out.

5

Patient Review

4/1/2010

Sandostatin for Carcinoid Syndrome

This drug worked great for my initial problem, but I developed some serious side effects. I had to have my gall bladder removed, and now my glucose is rising each month. Fingers crossed that I don't develop diabetes as a result.

5

Patient Review

4/11/2015

Sandostatin for Carcinoid Syndrome

From my experience, this drug does not mix well with warfarin.

4.7

Patient Review

12/26/2008

Sandostatin for Syndrome After Rapid Passage of Food Into Small Intestine

I was having four bouts of diarrhea a day, but this medication has brought that number down to just one.

4.3

Patient Review

4/24/2013

Sandostatin for Carcinoid Crisis

I have a rare form of cancer that has metastasized to my liver. My doctor prescribed this medication to me in order to help shrink or stabilize the growth of the tumors, which it has done over the course of three years. I haven't experienced any negative side effects from the monthly injections.

4.3

Patient Review

1/13/2017

Sandostatin for Carcinoid Syndrome

After diagnosis and beginning injections, I remained stable for years. I believe the sandostatin was largely responsible. Recently, there was some disease progression so I had a chemo-embolization procedure which shrunk the largest tumors (liver). that brought all my liver enzymes back to normal and chromogranin and 5-HIAA to their lowest levels since they started measuring them.

3.7

Patient Review

10/24/2009

Sandostatin for Carcinoid Syndrome

This medication has been an absolute life-saver. I was completely housebound due to my severe diarrhea, but this treatment regimen has allowed me to live a normal life again. The monthly shot is painful, but it's worth it for the relief that it provides.

3.7

Patient Review

8/21/2009

Sandostatin for Carcinoid Crisis

I've been getting monthly injections from my doctor to treat my carcinoid cancer. So far, it's been working great for the past five months!

3.3

Patient Review

3/10/2008

Sandostatin for Carcinoid Syndrome

3

Patient Review

2/20/2010

Sandostatin for Carcinoid Syndrome

I've been getting a 30mg shot every three weeks since February of 2000. I was originally only given six months to live, so I'm surprised and grateful that this treatment has kept me alive for so long. Although the shots are incredibly painful for about a week afterwards.

2.7

Patient Review

12/24/2015

Sandostatin for Chylothorax

My oncologist started me on injections 18 months ago for carcinoid tumors in my liver and spleen. I don't have carcinoid syndrome, but so far the tumors are stable.

1.7

Patient Review

4/3/2008

Sandostatin for Carcinoid Crisis

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about sandostatin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Sandostatin a chemotherapy?

"Sandostatin is not a chemotherapy drug. It is a man-made hormone that has similar effects to somatostatin, a hormone produced naturally in our bodies."

Answered by AI

What is the side effects of Sandostatin?

"The six most common symptoms of Covid-19 are: back pain, fatigue, headache, abdominal pain, nausea, and dizziness."

Answered by AI

What is the drug Sandostatin used for?

"Sandostatin and Sandostatin LAR Depot are FDA-approved drugs used to treat severe diarrhea and flushing (a feeling of warmth and redness in your skin) caused by metastatic carcinoid tumors. Carcinoid tumors are a type of cancer that usually starts in your lungs or digestive system."

Answered by AI

What is octreotide Sandostatin used for?

"Octreotide is used to treat symptoms caused by certain types of tumors, such as severe watery diarrhea, sudden reddening of the face and neck, that are usually found in the intestines and pancreas."

Answered by AI

Clinical Trials for Sandostatin

Image of Stanford Digestive Health Clinic in Redwood City, United States.

MITI-001 for Irritable Bowel Syndrome

18 - 65
All Sexes
Redwood City, CA

While the pathophysiology of diarrhea-predominant irritable bowel syndrome (IBS-D) is complex and heterogeneous, dysbiosis of the gut microbiome is frequently observed, suggesting that a substantial subset of patients with irritable bowel syndrome (IBS) have symptoms that are initiated and/or perpetuated by a microbiome dysfunction. Successful randomized controlled trials (RCT) for IBS-D (Ford 2018; Black 2022) leveraging microbiome-targeted therapies (antibiotics or low microbiome fermentation diets) suggest the gut microbiome is at least partially involved in IBS symptoms. Furthermore, fecal microbiota transplantation (FMT) for patients with IBS-D has demonstrated promising results (El-Salhy 2020), supporting the possibility that altering the microbiome composition could ameliorate IBS-D symptoms. MITI-001 is a transplantable gut bacterial community composed of 157 live bacterial strains, encompassing 79 genera of commensal bacteria, that have been isolated from healthy donor stool, purified, and banked. The hypothesis of the proposed research is that MITI-001 can target the pathophysiologic lesion in a subset of IBS-D patients, restore the altered microbial metabolic process, and thus alleviate IBS-D symptoms.

Phase < 1
Waitlist Available

Stanford Digestive Health Clinic (+1 Sites)

Sean P Spencer, MD, PhD

Have you considered Sandostatin clinical trials?

We made a collection of clinical trials featuring Sandostatin, we think they might fit your search criteria.
Go to Trials

Have you considered Sandostatin clinical trials?

We made a collection of clinical trials featuring Sandostatin, we think they might fit your search criteria.
Go to Trials

Have you considered Sandostatin clinical trials?

We made a collection of clinical trials featuring Sandostatin, we think they might fit your search criteria.
Go to Trials